Abnormally high plasma concentrations of M-4, the active metabolite of edoxaban, at the onset of acute kidney injury in a patient receiving rifampin and clarithromycin: a case report
This case suggests that in patients with impaired renal function taking edoxaban, co-administration of carboxylesterase-1 inducers such as rifampin and/or OATP1B1 inhibitors such as rifampin or clarithromycin may increase plasma concentrations of M-4 to clinically non-negligible levels.
Authors
- Kenichi Hakamada (ORCID: https://orcid.org/0000-0001-6513-1202)
- Hayato Nagase
- Ishido Keinosuke
- Norihisa Kimura (ORCID: https://orcid.org/0000-0002-0585-3024)
- Yusuke Wakasa (ORCID: https://orcid.org/0000-0001-9106-6002)
- Junichi Nakagawa (ORCID: https://orcid.org/0000-0003-2340-2267)
- Takenori Niioka (ORCID: https://orcid.org/0000-0002-4560-6423)
- Satoshi Yokoyama (ORCID: https://orcid.org/0000-0003-3031-6287)
- Kayo Ueno
Institutions
- Hirosaki University (JP)
- Hirosaki University Hospital (JP)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1186/s40780-024-00390-6
- Citations
- 2
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.90
Funders
- Japan Society for the Promotion of Science